Cover Image
市場調查報告書

帕金森氏症:開發中產品分析

Parkinson's Disease - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 229809
出版日期 內容資訊 英文 831 Pages
訂單完成後即時交付
價格
Back to Top
帕金森氏症:開發中產品分析 Parkinson's Disease - Pipeline Review, H2 2017
出版日期: 2017年12月21日 內容資訊: 英文 831 Pages
簡介

帕金森氏症,是有運動功能障礙特徵的神經退化性疾病,靜下時顫抖,肌肉僵硬,運動器官的功能障礙。原因有年齡、遺傳要素、頭部外傷、環境要素、荷爾蒙的變化等。 帕金森氏症造成神經原功能異常,也可能導致神經原死亡。神經原,擔負著信號傳達原的神經傳達物質多巴胺的合成,神經原受到影響阻礙神經有效的傳達,使運動功能和肌肉的調整力下降。

本報告提供帕金森氏症的治療藥開發平台的現狀及最新更新的各開發階段比較分析,企業和研究機關開發中的治療藥,治療藥的評估,後期階段及中止的計劃相關資訊等最新的新聞和發表。

簡介

帕金森氏症概要

治療藥的開發

帕金森氏症:企業開發中的治療藥

帕金森氏症:大學/機關研究中的治療藥

帕金森氏症:開發中產品概況

帕金森氏症:企業開發中的產品

帕金森氏症:大學/機關研究中的產品

帕金森氏症的治療藥開發作的企業

帕金森氏症:治療藥的評估

藥物簡介

帕金森氏症:暫停中的計劃

帕金森氏症:開發中止的產品

帕金森氏症:產品開發的里程碑

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9964IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Parkinson's Disease - Pipeline Review, H2 2017, provides an overview of the Parkinson's Disease (Central Nervous System) pipeline landscape.

Parkinson's disease is a neurodegenerative disorder characterized by movement dysfunctions. It causes involuntary shaking, stiffness and impaired locomotory functions. Age, genetic factors, head trauma, environmental factors, hormonal changes, etc are predisposing factors for Parkinson's disease. Parkinson's disease results in abnormal functioning or death of neurons. The neurons are responsible for the synthesis of neurotransmitter dopamine which is further responsible for the transmission of signals. The effect on the neurons blocks effective neurotransmission and may lead to eventual decline in movement and coordination.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Parkinson's Disease - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Parkinson's Disease (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Parkinson's Disease (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Parkinson's Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 2, 8, 41, 42, 4, 190, 50 and 7 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 46 and 13 molecules, respectively.

Parkinson's Disease (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Parkinson's Disease (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Parkinson's Disease (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Parkinson's Disease (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Parkinson's Disease (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Parkinson's Disease (Central Nervous System)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Parkinson's Disease (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Parkinson's Disease (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Parkinson's Disease - Overview
  • Parkinson's Disease - Therapeutics Development
  • Parkinson's Disease - Therapeutics Assessment
  • Parkinson's Disease - Companies Involved in Therapeutics Development
  • Parkinson's Disease - Drug Profiles
  • Parkinson's Disease - Dormant Projects
  • Parkinson's Disease - Discontinued Products
  • Parkinson's Disease - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Parkinson's Disease, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..4), H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..5), H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..6), H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..7), H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..8), H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..9), H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..10), H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..11), H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..12), H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..13), H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017 (Contd..2), H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..2), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..3), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..4), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..5), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..6), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..7), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..8), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..9), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..10), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..11), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..12), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..13), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..14), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..15), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..16), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..17), H2 2017
  • Products under Development by Universities/Institutes, H2 2017
  • Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017
  • Products under Development by Universities/Institutes, H2 2017 (Contd..2), H2 2017
  • Products under Development by Universities/Institutes, H2 2017 (Contd..3), H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017
  • Number of Products by Stage and Target, H2 2017 (Contd..2), H2 2017
  • Number of Products by Stage and Target, H2 2017 (Contd..3), H2 2017
  • Number of Products by Stage and Target, H2 2017 (Contd..4), H2 2017
  • Number of Products by Stage and Target, H2 2017 (Contd..5), H2 2017
  • Number of Products by Stage and Target, H2 2017 (Contd..6), H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..2), H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..3), H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..4), H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..5), H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..6), H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Parkinson's Disease - Pipeline by 2-BBB Medicines BV, H2 2017
  • Parkinson's Disease - Pipeline by 4P Therapeutics LLC, H2 2017
  • Parkinson's Disease - Pipeline by AbbVie Inc, H2 2017
  • Parkinson's Disease - Pipeline by AC Immune SA, H2 2017
  • Parkinson's Disease - Pipeline by Acorda Therapeutics Inc, H2 2017
  • Parkinson's Disease - Pipeline by Adamas Pharmaceuticals Inc, H2 2017
  • Parkinson's Disease - Pipeline by Addex Therapeutics Ltd, H2 2017
  • Parkinson's Disease - Pipeline by Aeolus Pharmaceuticals Inc, H2 2017
  • Parkinson's Disease - Pipeline by AFFiRiS AG, H2 2017
  • Parkinson's Disease - Pipeline by Amabiotics SAS, H2 2017
  • Parkinson's Disease - Pipeline by Amarantus Bioscience Holdings Inc, H2 2017
  • Parkinson's Disease - Pipeline by American Gene Technologies International Inc, H2 2017
  • Parkinson's Disease - Pipeline by Anavex Life Sciences Corp, H2 2017
  • Parkinson's Disease - Pipeline by Antoxis Ltd, H2 2017
  • Parkinson's Disease - Pipeline by Aoxing Pharmaceutical Company Inc, H2 2017
  • Parkinson's Disease - Pipeline by APeT Holding BV, H2 2017
  • Parkinson's Disease - Pipeline by ApoPharma Inc, H2 2017
  • Parkinson's Disease - Pipeline by Aposense Ltd, H2 2017

List of Figures

  • Number of Products under Development for Parkinson's Disease, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Top 10 Targets, H2 2017
  • Number of Products by Stage and Top 10 Targets, H2 2017
  • Number of Products by Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Top 10 Routes of Administration, H2 2017
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2017
  • Number of Products by Top 10 Molecule Types, H2 2017
  • Number of Products by Stage and Top 10 Molecule Types, H2 2017
Back to Top